Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q3 2015 · 10-Q
Revenue—
Net Income-$3.95M-$3.95MN/M vs Q3 2014 EPS Diluted-$0.10-$0.10N/M vs Q3 2014 Operating Income-$4,639,814N/M Operating Cash Flowderived-$3,499,260N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,525,246N/M ended Sep 30, 2015 · filed Oct 30, 2015 · 30 d after period end